Summary : This flowchart presents an algorithm for antiretroviral management of infants with in utero or intrapartum HIV exposure, stratified by risk of HIV transmission based on maternal HIV RNA levels and timing of viremia. flowchart: # Nodes : • Start (rectangle): "HIV RNA ≥50 copies/mL at any point after 20 weeks’ gestation?" • Decision (diamond): "YES" / "NO" branches. • Decision (rectangle): "Did this viremia occur in the 4 weeks prior to delivery?" • Decision (diamond): "YES" / "NO" branches. • High Risk (rectangle, pink): "High Risk of In Utero and Intrapartum HIV Transmission" – "Birth HIV NAT, PLUS" – "Three-drug presumptive HIV therapy regimen for 2–6 weeks*" – "*Note: ZDV prophylaxis for 6 weeks total (see Table 13)" • Intermediate Risk (rectangle, peach): "Infant ARV Management Decision-Making Guided by Clinical Scenario" – "Birth HIV NAT, followed by a three-drug presumptive HIV therapy regimen for 2–6 weeks." – "If the birth PCR is negative, de-escalate to ZDV alone to complete ZDV prophylaxis for 2–6 weeks total (see Table 13)." – "OR" – "ZDV prophylaxis for 2–6 weeks total (see Table 13)" • Low Risk (rectangle, green): "Low Risk of HIV Transmission" – "ZDV prophylaxis for 2 weeks total" # Connectors : • Arrow from Start node splits to YES and NO. • YES branch leads to "Did this viremia occur in the 4 weeks prior to delivery?" node. • NO branch leads directly to "Low Risk of HIV Transmission" node. • From "Did this viremia occur..." node, YES leads to "High Risk..." node, NO leads to "Infant ARV Management..." node. # Layout : • Top-down hierarchical flow. • Initial decision splits into two main branches (YES/NO). • YES branch has a secondary decision, further splitting into two risk categories. • NO branch leads directly to low risk management. # Analysis : • The algorithm stratifies infants into high, intermediate, or low risk for HIV transmission based on maternal HIV RNA levels and timing of viremia. • High risk infants receive more intensive ARV therapy (three-drug regimen and longer ZDV prophylaxis). • Intermediate risk infants have management tailored by clinical scenario, with possible de-escalation based on birth PCR results. • Low risk infants receive only short-course ZDV prophylaxis. • The flowchart ensures that infants at greatest risk receive the most aggressive prophylaxis, while minimizing unnecessary treatment for low-risk cases.

Summary : This figure presents a suggested algorithm for the critical care management of acute-on-chronic liver failure in cirrhosis, outlining stepwise assessment and interventions for various clinical scenarios including hepatic encephalopathy, hypoxemia, hypovolemia, anemia, and septic shock, with specific recommendations for investigations, infection treatment, and general supportive measures. flowchart: # Nodes : • Hepatic encephalopathy grade III, IV (rectangle, red) • Hypoxemia Pa O2 ≤ 80 mm Hg (rectangle, red) • Hypovolemia (rectangle, red) • Hemoglobin < 7 g/dL (rectangle, red) • MAP < 60 mm Hg see Septic shock (rectangle, red) • SEPSIS Evaluation (rectangle, red) • Airway protection (rectangle, white) • Chest X-ray/CT. Evaluate for HPS, Consider therapeutic para/thoracentesis as needed, ↑FiO2, and consider ventilation (rectangle, white) • Volume challenge using echocardiogram monitoring (rectangle, white) • Transfuse PRBC to Hgb > 7g/dL or > 9g/dL with cardiovascular risk factors (rectangle, white) • Assess volume, evaluation for GI Bleeding, Sepsis evaluation (rectangle, white) • Investigations (rectangle, pink) • Paracentesis, Culture blood, ascites, urine, Chest X-ray, Lactate (rectangle, white) • Treat infection (rectangle, pink) • Vancomycin 15 mg/kg Q 6H, Meropenem 1 gm Q 8H, Antifungal therapy if inadequate response 48 hours (rectangle, white) • General measures (rectangle, pink) • Fluid resuscitation within 3 hours, Therapeutic paracentesis, Aspiration precautions, DVT prophylaxis, Stress ulcer prophylaxis (rectangle, white) • MAP < 60 mm Hg Septic shock (rectangle, pink) • Norepinephrine Infusion (rectangle, white) • MAP < 60 mm Hg Persistent shock (rectangle, pink) • Hydrocortisone 50 mg Q 6 h (rectangle, white) # Connectors : • Each red rectangle (clinical scenario) connects rightward to a specific white rectangle (intervention or assessment). • SEPSIS Evaluation leads to a vertical sequence of pink rectangles: Investigations → Treat infection → General measures → MAP < 60 mm Hg Septic shock → MAP < 60 mm Hg Persistent shock. • Each pink rectangle is followed by a white rectangle detailing specific actions. • The flow is primarily left-to-right for initial assessment, then top-to-bottom for sepsis management. # Layout : • The diagram is organized in three main vertical columns: – Left: Red rectangles for initial clinical findings. – Middle: White rectangles for immediate interventions. – Right: Pink rectangles for sepsis evaluation and management, with white rectangles for detailed steps. • The sepsis management column is a vertical sequence, with each step leading to the next. # Analysis : • The algorithm provides a structured, stepwise approach for managing acute-on-chronic liver failure in cirrhosis, prioritizing airway protection, oxygenation, volume status, anemia correction, and sepsis evaluation. • Sepsis management is detailed, with specific recommendations for investigations, antimicrobial therapy, supportive measures, and escalation to vasopressors and steroids for persistent shock. • The flowchart emphasizes early identification and targeted intervention for each critical issue, integrating both general and specific measures for optimal patient care.

Summary : This flowchart provides a comprehensive management algorithm for adults with atopic dermatitis, detailing baseline management, topical therapies, phototherapy, and systemic therapies, including FDA-approved and recommended treatments, maintenance strategies, and escalation steps for inadequate control. flowchart: # Baseline Management : • Severity Assessment: Assessment of signs of disease, severity of symptoms, comorbidities, and impact on quality of life (QOL). • Exacerbating Factor Avoidance: Identify trigger factors (allergens, irritants, etc.) and counsel patients on avoidance. • Baseline Therapy: Moisturizers/Emollients (strong recommendation), Bathing Practices (conditional recommendation). # Initial Pathways : • Mild to Severe: Proceed to Topical Therapies. • Moderate to Severe: Proceed to Phototherapy & Systemic Therapy. # Topical Therapies : ## Optimized Topical Therapy for Inflamed Areas : • TCS (Topical corticosteroids) (FDA, strong recommendation) • TCIs (Topical calcineurin inhibitors) (FDA, strong recommendation) • Crisaborole ointment (FDA, strong recommendation) • Ruxolitinib cream (FDA, strong recommendation) • Wet Dressings (strong recommendation) ## Ongoing Maintenance with Topical Therapies : • Reactive or proactive application for maintenance. • Shared decision-making for long-term treatment. • Consider patient satisfaction and adherence. ## Inadequate Control : • If topical therapy and basic management optimized, consider alternative diagnoses. • Consider additional treatment with phototherapy and/or systemic agents. # Phototherapy & Systemic Therapy : • Topical agents can be used concurrently with phototherapy or systemic agents for maintenance, rescue, or flares. # Phototherapy : • No specific agents listed; included as a treatment option for moderate to severe cases. # Systemic Therapies : ## Biologics : • Dupilumab (FDA, strong recommendation) • Tralokinumab (FDA, strong recommendation) ## JAK Inhibitors : • Upadacitinib (FDA, strong recommendation) • Abrocitinib (FDA, strong recommendation) • Baricitinib (strong recommendation) ## Immunosuppressants : • Methotrexate (strong recommendation) • Azathioprine (strong recommendation) • Cyclosporine (strong recommendation) • Mycophenolate mofetil (strong recommendation) • Systemic corticosteroids (FDA, strong recommendation against use) # Key : • Green circle: Strong recommendation in favor. • Yellow circle: Conditional recommendation in favor. • Red circle: Strong recommendation against. • Orange circle: Conditional recommendation against. • FDA: Indicated for atopic dermatitis. # Abbreviations : • QOL: Quality of Life • FDA: Food and Drug Administration • TCS: Topical corticosteroids • TCI: Topical calcineurin inhibitor # Layout : • The flowchart is organized from baseline management at the top, splitting into two main pathways (mild to severe and moderate to severe), with further branches into topical, phototherapy, and systemic therapies. • Maintenance and escalation steps are included for ongoing management and inadequate control. # Analysis : • The algorithm emphasizes starting with baseline management and topical therapies, escalating to phototherapy and systemic therapies for more severe or refractory cases. • Strong recommendations are visually highlighted for first-line agents, with systemic corticosteroids strongly discouraged. • FDA-approved options are clearly marked, supporting evidence-based decision-making. • The flowchart supports a stepwise, patient-centered approach, integrating maintenance and escalation strategies.